Breast cancer screening in transgenders: an integrative literature review
DOI:
https://doi.org/10.33448/rsd-v11i17.38953Keywords:
Breasts neoplasms; Hormone replacement therapy; Mass screening; Transgender.Abstract
Introduction: Breast cancer, with the exception of non-melanoma skin cancer, is the most frequent in Brazil. Breast cancer is stratified into subtypes according to its genesis. Estrogen, in turn, is a steroid hormone that is related to the origin of hormone-dependent breast cancer. In this context, hormone therapy, used in the treatment of menopausal symptoms and also in hormone therapy for transgenders, is directly involved with the volume of estrogen circulating in the body of these groups. Objective: Given the above, there is concern about the increased incidence of breast cancer in transgenders. Therefore, this literature review aimed to evaluate the relationship between breast cancer and hormone therapy in the long term, and also, the status of breast cancer screening in women and transgender men, as well as its challenges. Methodology: Literary review, resulting from searches in VHL, PubMed, EbscoHost and SciELO covering articles in English, Portuguese and Spanish. Results: Twelve articles were analyzed. It was evidenced in the literature insufficient documentation for a possible affirmation or denial of the relationship between hormone therapy and higher incidence of breast cancer in transgenders, due to the lack of studies. Conclusion: It is necessary that the epidemiology be better understood, so that there is some proper guideline regarding secondary prevention in transgender people, in addition to better preparation of professionals for quality care. Still, it is suggested that this population be better documented, in order to have more studies and specific policies.
References
Calas, M. J. G., et al. (2022). Integrative review on breast cancer screening in the transgender population: what do we know? Mastology, 32, 96-102. https://doi.org/10.29289/2594539420210051
Carvalho, M. S., et al. (2021). Desafios do rastreio do câncer de mama em pessoas transgêneros. Research, Society and Development, 10(9), e11810917772. http://dx.doi.org/10.33448/rsd-v10i9.17772
Castro, A. D., & Nagelberg, A. (2019). Screening mamario en pacientes transgénero bajo tratamiento hormonal cruzado (thc): Situación actual y controversias. Revista Argentina de Mastología, 38(137), 116-32. https://www.revistasamas.org.ar/revistas/2019_v38_n137/10.pdf
de Blok, C. J. M., Wiepjes, C. M., Nota, N. M., van Engelen, K., Adank, M. A., Dreijerink, K. M. A., Barbé, E., Konings, I. R. H. M., & den Heijer, M. (2019). Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ (Clinical research ed.), 365, l1652. https://doi.org/10.1136/bmj.l1652
Filho, G. B. (2021). Bogliolo - Patologia. Grupo GEN, (9a ed.).
Hall, J. E., & Hall, M. E. (2021). Guyton & Hall - Tratado de Fisiologia Médica. Grupo GEN, (14a ed.).
Hartley, R. L., & Temple-Oberle, C. (2018). Breast cancer in transgender patients: A systematic review. Part 1: Male to female. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 44(10), 1455–1462. https://doi.org/10.1016/j.ejso.2018.06.035
INCA. (2021). Dados e números sobre o câncer de mama. https://www.as.saude.ms.gov.br/wp-content/uploads/2021/11/ Dados_e_numeros_site_cancer_mama_2021-1.pdf
Kiran, T., et al. (2019). Cancer screening rates among transgender adults: Cross-sectional analysis of primary care data. Canadian family physician Medecin de famille canadien, 65(1), 30–37. https://www.cfp.ca/content/65/1/e30.long
Ministério da Saúde. (2022). Incidência. Gov. https://www.gov.br/inca/pt-br/assuntos/gestor-e-profissional-de-saude/controle-do-cancer-de-mama/dados-e-numeros/incidencia#:~:text=Leaflet-,Fonte%3A%20INCA%2C%202022.,doen%C3%A7a%20(INCA%2C%202019b).
Ministério da Saúde. (2010). Rastreamento. Série A. Normas e Manuais Técnicos Cadernos de Atenção Primária, n. 29. Brasília: Ministério da Saúde.
Nayaran, A., et al. (2017). Breast cancer screening in transgender patients: findings from the 2014 BRFSS survey. Breast cancer research and treatment, 166(3), 875–879. https://doi.org/10.1007/s10549-017-4461-8
Organização Mundial da Saúde. (2015). Saúde sexual, direitos humanos e a lei.
Parikh, U., et al. (2020). Breast Imaging in Transgender Patients: What the Radiologist Should Know. Radiographics, 40(1), 13–27. https://doi.org/10.1148/rg.2020190044
Patel, H., et al. (2020). Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review. Endocrine, 68(1), 6–15. https://doi.org/10.1007/s12020-020-02197-5
Porto, C. C. (2019). Semiologia Médica, (8a ed.). Grupo GEN. 881-896.
Sonnenblick, E. B., et al. (2018). Breast Imaging of Transgender Individuals: A Review. Current radiology reports, 6(1), 1. https://doi.org/10.1007/s40134-018-0260-1
Stone, J. P., & Temple-Oberle, C. (2018). Breast cancer in transgender patients: A systematic review. Part 2: Female to Male. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 44(10), 1463–1468. https://doi.org/10.1016/j.ejso.2018.06.021
Souza, M. T., et al. (2010). Revisão integrativa: o que é e como fazer. Einstein, 8(1), 102-6.
Tanini, S., et al. (2019). Testosterone and Breast Cancer in Transmen: Case Reports, Review of the Literature, and Clinical Observation. Clinical breast cancer, 19(2), 271–275. https://doi.org/10.1016/j.clbc.2018.12.006
World professional association for transgender health - WPATH. (2012). Normas de atenção à saúde das pessoas trans e com variabilidade de gênero. Sétima edição.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Willian Júnio Rodrigues Mendonça; Nara Jane Mendonça; Paula Marynela Alves Pereira Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
